Vivus shares pop on diet pill demand

Analyst predicts it will take time, however, before Qsymia records meaningful revenue.

By Oct 9, 2012 2:28PM
Pills copyright CorbisDiet pill maker Vivus (VVUS) saw demand rise substantially for its weight-loss drug Qsymia in the second week on the market. Some insurers appear to be covering the product.

The sales figures were a cause for celebration among investors, at least for a short spell. Shares of Vivus rose 10% Monday to close at $20.44. The stock rose another 2% Tuesday morning, but pared gains by early afternoon, trading around $20.50.

With the hype around recently approved diet drugs from Vivus and rival Arena Pharmaceuticals (ARNA), sales figures will certainly be a significant guidepost for investors.

Both stocks enjoyed big rallies this year. Vivus shares more than doubled, while Arena jumped 370%. Arena's drug, Belviq, is approved by the U.S. Food and Drug Administration but is still being reviewed by the U.S. Drug Enforcement Administration because of potential for abuse. The pill is expected to be on the market by late this year or early 2013. Arena's development partner, Japanese drugmaker Eisai, will sell Belviq.

Two drug-tracking companies, IMS Health and Wolters Kluwer, reported substantial gains for Qsymia in the second week of sales, which ended Sept. 28. The numbers vary quite a bit and it should be noted that these are quite early figures.

According to Cowen & Co. analyst Simos Simeonidis, IMS reports 933 new prescriptions compared with 236 the first week, and Wolters Kluwer said there were 581 new prescriptions vs. 106 the first week.

"Even though we believe it is too early in the launch to call anything a trend, we see the four- and five-fold increase in the IMS and Wolters Kluwer numbers as a positive early sign for Qsymia’s demand," Simeonidis says.

So why does the analyst have a hold rating on the stock?

Simeonidis says he believes that Qsymia will be a big-selling drug -- $1.6 billion by 2019. But he also says the ramp-up will be slower than some investors think. Vivus and Arena just won approvals for the first new diet pills in the U.S. in 13 years. Both companies are appealing to doctors' concerns that obesity has become an epidemic, leading to a host of related diseases. The long stretch of time between the new drugs and past approvals is a reflection of the safety concerns associated with these type of products.  

"The Qsymia launch will be a slow one, given that the company will have to build out awareness for both the disease and the drug," Simeonidis says.

Vivus is trying to create demand for a drug with physician obesity specialists through a 150-person sales force, which is a challenge, Simeonidis says. He predicts shares will "remain range bound" for the next nine to 12 months.

Meanwhile, Bloomberg reported earlier this month that 30% of health insurers were covering the pill. Qsymia is only distributed through mail order pharmacies and the major players in that business, including Express Scripts (ESRX), Walgreen (WAG) and CVS Caremark (CVS), have all lined up to sell the drug, Vivus says. It costs about $4 to $6 a pill, depending on the dosage.

Orexigen Therapeutics (OREX) also is testing a diet pill that it hopes to eventually bring to market to compete with Vivus and Arena's drugs.

More from Minyanville



Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

123 rated 1
266 rated 2
485 rated 3
660 rated 4
586 rated 5
652 rated 6
640 rated 7
504 rated 8
289 rated 9
159 rated 10

Top Picks

TAT&T Inc9



Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.